Samsung and Bioepis launch third Humira biosimilar in Europe

pharmafile | October 17, 2018 | News story | Research and Development, Sales and Marketing Amgen, Biogen, Humira, Imraldi, Samusng Bioepis, pharma 

Hot on the heels of Amgen, Samsung Bioepis and Biogen have announced the launch of their own biosimilar version of Abbvie’s best-selling drug Humira (adalimumab) in Europe.

Like its reference product, it is authorised for use in a range of indications including rheumatoid and psoriatic arthritis, axial spondyloarthritis, psoriasis, Crohn’s disease, ulcerative colitis and uveitis, as well as Crohn’s disease, paediatric plaque psoriasis and idiopathic arthritis in children.

Imraldi, as the pair’s product is known, is the third anti-TNF biosimilar from Biogen’s portfolio in Europe, alongside its own version of Amgen’s Enbrel, known as Benpali, and of Janssen’s Remicade, known as Flixabi.  

The launch sets up Imraldi to go head-to-head with Amgen’s Amgevita and Novartis’ Hyrimoz for a share of Humira’s unrivalled sales, which reached $18 billion in global revenue last year – $4 billion of this was in Europe alone.

“We are proud to be pioneering innovation in biosimilars to help transform the lives of people in Europe with chronic autoimmune conditions,” remarked Ian Henshaw, Global Head of Biosimilars at Biogen. “With the addition of Imraldi to our anti-TNF biosimilar offering, we are increasing physician choice and patient access in Europe to affordable treatments across disease areas.”

Matt Fellows

Related Content

Amgen opens new biomanufacturing facility in Ohio, US

Amgen has announced that it has opened a new manufacturing site in Central Ohio, US. …

robina-weermeijer-so1l3jsdd3y-unsplash_2

Eisai shares new data for Leqembi for Alzheimer’s treatment

Eisai and Biogen have announced that Eisai has shared new data for Leqembi (lecanemab-irmb) 100mg/mL …

Biogen’s biosimilar Tofidence approved by FDA

Biogen has announced that the US Food and Drug Administration (FDA) has approved Tofidence (tocilizumab-bavi) …

Latest content